Fi­bro­Gen grap­ples with PhI­II set­back in Duchenne mus­cu­lar dy­s­tro­phy

Fi­bro­Gen’s top an­ti­body can­di­date has failed a Phase III study in Duchenne mus­cu­lar dy­s­tro­phy, mark­ing a dis­ap­point­ing start to a string of read­outs slat­ed for the next few months.

Dubbed pam­revlum­ab, the drug is list­ed as a lead can­di­date for Fi­bro­Gen along­side rox­adu­s­tat — an ane­mia drug that’s run in­to mul­ti­ple clin­i­cal and reg­u­la­to­ry set­backs of its own. Shares $FGEN fell 9% to be­low $17 in pre-mar­ket trad­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER